2 recruiting, 1 active not recruiting, 1 unknown. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Unknown 1 |
Follow Mutation Carrier Screening: new trials by email Literature Review of Mutation Carrier Screening trials Research Report on Mutation Carrier Screening
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-11-02 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-11-18 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-11-13 |
| Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men physiologic testing, study of socioeconomic and demographic variables, evaluation of cancer risk factors - Prostate Cancer | Phase 2 | Unknown | Lawrence Livermore National Laboratory at University of California | 800 | 2002-03-01 | 2013-09-20 |
Central Nervous System Neoplasms (1) · Endometrial Neoplasms (1) · Ependymoma (1) · Fallopian Tube Neoplasms (1) · Glioma (1) · Hepatoblastoma (1) · Histiocytic Sarcoma (1) · Histiocytosis, Langerhans-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Medulloblastoma (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Neoplasm Metastasis (1) · Neuroblastoma (1)
National Cancer Institute (NCI) (3) · Lawrence Livermore National Laboratory at University of California (1)
United States (4) · Puerto Rico (3) · Canada (2) · Australia (1)
Donald W Parsons (1) · James M Ford (1) · Jerald P Radich (1) · Kenneth T. Bogen, DrPH, MPH, MA, ScD (1)
PMID 33591402, PMID 35353553, PMID 36902217, PMID 41166674, PMID 42686334
U10CA180820 (1), U10CA180886 (1), U10CA180888 (1)